REVIEW Diamonds Are Forever: the Cortisone Legacy

Total Page:16

File Type:pdf, Size:1020Kb

REVIEW Diamonds Are Forever: the Cortisone Legacy 1 REVIEW Diamonds are forever: the cortisone legacy Stephen G Hillier, The Queen’s Medical Research Institute, Centre for Reproductive Biology, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK (Requests for offprints should be addressed to S G Hillier; Email: [email protected]) This article is based on the Jubilee Medal lecture delivered by Prof. Hillier in November 2006 celebrating the Diamond Jubilee of the Society for Endocrinology Abstract The year 1946 was not only the year that the Society for developments in endocrinology ever since. This article Endocrinology was founded, but also the year that Edward surveys the extraordinary cortisone timeline, from first Kendall’s compound E (cortisone) was first synthesised by synthesis until now. The concluding scientific message is Louis Sarett. By 1948, sufficient quantities of compound E that intracrine metabolism of cortisone to cortisol via were available for the rheumatologist Philip Hench to test it 11bhydroxysteroid dehydrogenase type 1 likely sustains local successfully for the first time in a patient with rheumatoid amplification of glucocorticoid action at sites of inflammation arthritis. It was immediately hailed as a ‘wonder drug’ and was throughout the body. The broader message is that the shown to be effective in a number of inflammation-associated discovery of compound E by Kendall (basic scientist), its conditions, most notably rheumatoid arthritis. The sub- large-scale synthesis by Sarett (industrial chemist) and its sequent development of endocrinology as a discipline is therapeutic application by Hench (rheumatologist) serves as a inextricably linked to the chemistry, biology and medicine of paradigm for modern translational medicine. It is concluded anti-inflammatory glucocorticoids. Sixty years after the first that endocrinology will remain a force in health and disease if chemical synthesis of cortisone, corticosteroids remain among it continues to evolve sans frontie`res at the basic/applied/cli- the top ten most commonly used prescription and over the nical science interface. A challenge for the Society for counter drugs. Basic and clinical studies of glucocorticoid Endocrinology is to ensure this happens. biosynthesis, metabolism and action have trail-blazed Journal of Endocrinology (2007) 195, 1–6 Introduction synthesis and therapeutic applications are celebrated as a paradigm for modern translational medicine. The Society for Endocrinology was founded in 1946 ‘to promote the advance of endocrinology by observational or clinical studies’. The year 1946 was also the year that Lewis The steroid rush Hastings Sarett, an organic chemist at Merck Research Labs in the USA, published the first synthesis of a recently discovered The bedrock of the Society for Endocrinology is steroid adrenal steroid hormone named ‘compound E’ (Sarett 1946). chemistry, which entered its heyday during the 1930s. Compound E had been crystallised from bovine adrenal Landmark developments around that time included elucida- glands 10 years earlier by Edward Calvin Kendall (Mason et al. tion of the signature perhydrocyclo-pentanophenanthrene 1936). Kendall’s compound E would eventually be known as steroid structure by Otto Rosenheim and Harold King in ‘cortisone’ (Kendall 1953) and become one of the wonder 1932 (Feiser & Feiser 1959) and introduction of the general drugs of the 20th century. Hence, 2006 was the diamond name ‘steroid’ in 1936 to cover all compounds with a sterol- jubilee year of both the UK Society of Endocrinology and the like skeleton (Klyne 1957). The sex steroids oestradiol, first synthesis of compound E. This brief review traces the testosterone and progesterone were discovered between 1929 impact of cortisone on the development of steroid and 1935, followed by the adrenocortical hormones, endocrinology from then until now. The concept is advanced cortisone and cortisol, in 1935–1938. By 1937, most of the that its intracrine activation to cortisol at sites of inflammation classic steroid hormones had been isolated and their structures supports both natural and therapeutic anti-inflammatory determined (Feiser & Feiser 1959). Following a hiatus during effects of cortisone. More broadly, cortisone’s discovery, WWII, the field was massively boosted in 1948 by the Journal of Endocrinology (2007) 195, 1–6 DOI: 10.1677/JOE-07-0309 0022–0795/07/0195–001 q 2007 Society for Endocrinology Printed in Great Britain Online version via http://www.endocrinology-journals.org Downloaded from Bioscientifica.com at 09/27/2021 04:06:58PM via free access 2 S G HILLIER . Cortisone and inflammation announcement of the dramatic therapeutic effects of cortisone By January 1950, Kendall & Hench had named compound E (see below) and the race to synthesise more and more steroid as cortisone to avoid its confusion with vitamin E (Kendall analogues with beneficial therapeutic effects. By 1956, 10 1964). In the same year, Kendall & Hench shared the Nobel years after the Society was founded, the number of novel Prize for Physiology or Medicine ‘for research on the steroidal substances synthesised had risen to over 7000 (Klyne structure and biological effects of adrenal cortex hormones’ 1957). During this period, the mineralocorticoid aldosterone with Tadeus Reichstein who had independently discovered was also discovered (Simpson et al. 1953). The first Society for cortisone at around the same time as Kendall and named it Endocrinology Medal was awarded to the co-discoverer of substance Fa (Reichstein 1936). aldosterone, James F Tait, in 1968. Significantly, the obverse prominently displays the perhydrocyclo-pentanophenan- threne steroid nucleus. Diamond decades Ever since it was ‘launched’ as a pharmaceutical in 1950 Kendall’s compounds (Kendall 1964), cortisone and a succession of closely related synthetic analogues have remained among the most widely Compound E was first isolated in 1935 from bovine adrenal prescribed medications in the world. At the same time, the glands along with a series of structurally related steroids science of endocrinology – particularly steroid endocrinology (including cortisol, then named compound F) capable of – has advanced beyond recognition. Understanding how improving muscular strength when administered to adrenal- cortisone is formed, metabolised and acts in health and disease ectomised rats or dogs (Mason et al. 1936, Reichstein 1936). has been integral to this progress, as is now considered. Individual steroid yields were only between 85 and 500 mg cortisone per 100 lb adrenal glands (Feiser & Feiser 1959). 1950s: steroid chemistry Therefore it was initially agreed that their use should be confined to small animals and none should be employed for Kendall (1964) initially believed it, ‘.highly improbable that clinical medicine (Hench 1964). The impetus to develop any product will ever be found which can be used in place of synthetic methods for adrenocorticosteroids came from the cortisone and the closely related compound F’. Compound F US entry into WWII in 1941, initially fuelled by a rumour (hydrocortisone; cortisol) quickly became the first topically that Luftwaffe pilots were taking adrenal extracts to increase applied corticosteroid effective in a variety of inflammatory their resistance to oxygen deprivation at high altitudes. skin disorders (Sulzberger & Witten 1952, Ravis & Eaglstein Although this rumour was unfounded, it is said to have kick- 2007). Meanwhile, cortisone was being hailed as a panacea for started the all-out quest for a large-scale synthetic route to the treating various diseases of unknown cause but with an active adrenal hormone, which at the time was given higher inflammatory basis. However, with high dosage and long- strategic priority than penicillin and anti-malarials (Quirke term usage, the remarkable therapeutic effects of cortisone 2005). Of the six biologically active steroids that had been were countered by undesirable side effects, such as excessive isolated from adrenal glands, Kendall’s compound A (11- salt and water retention, increased gastric acidity and dehydrocorticosterone) was initially targeted for synthesis psychosis. Considerable effort was therefore directed at because it possessed the simplest structure (Kendall 1964). chemical and microbiological syntheses of new cortisone Although synthetic ‘A’ proved to be active in animals, it had derivatives with lessened toxicity and improved efficacy no beneficial effects in patients with Addison’s disease. (Feiser & Feiser 1959). Progress was aided by the arrival of Therefore, attention turned to the closely related ‘E’ conformational analysis, which allowed molecular structures (cortisone), eventually leading to the historic 37-step and stereochemical confirmations to be assigned on the basis synthesis from desoxycholic acid published by Sarett (1946). of quantitative physiochemical parameters (Barton & By summer 1948, sufficient compound E was available for Cookson 1956). Milestones included the discovery that Kendall’s long-time collaborator at the Mayo Clinic, Philip whereas 9a-fluorination increased anti-inflammatory Showalter Hench, to test clinically. A pilot trial of compound potency, it also caused excessive protein loss, potassium loss, E on a patient with Addison’s disease was ‘encouraging’ sodium retention and oedema. On the other hand, (Kendall 1964). Then, on 21 September 1948, the first i.m. introduction of a 1,2 double bond in the A ring (to create injection of an aqueous suspension of compound E (100 mg) prednisone from cortisone and prednisolone
Recommended publications
  • Salivary 17 Α-Hydroxyprogesterone Enzyme Immunoassay Kit
    SALIVARY 17 α-HYDROXYPROGESTERONE ENZYME IMMUNOASSAY KIT For Research Use Only Not for use in Diagnostic Procedures Item No. 1-2602, (Single) 96-Well Kit; 1-2602-5, (5-Pack) 480 Wells Page | 1 TABLE OF CONTENTS Intended Use ................................................................................................. 3 Introduction ................................................................................................... 3 Test Principle ................................................................................................. 4 Safety Precautions ......................................................................................... 4 General Kit Use Advice .................................................................................... 5 Storage ......................................................................................................... 5 pH Indicator .................................................................................................. 5 Specimen Collection ....................................................................................... 6 Sample Handling and Preparation ................................................................... 6 Materials Supplied with Single Kit .................................................................... 7 Materials Needed But Not Supplied .................................................................. 8 Reagent Preparation ....................................................................................... 9 Procedure ...................................................................................................
    [Show full text]
  • Trials of Cortisone Analogues in the Treatment of Rheumatoid Arthritis
    Ann Rheum Dis: first published as 10.1136/ard.18.2.120 on 1 June 1959. Downloaded from Ann. rheum. Dis. (1959), 18, 120. TRIALS OF CORTISONE ANALOGUES IN THE TREATMENT OF RHEUMATOID ARTHRITIS BY H. W. FLADEE, G. R. NEWNS, W. D. SMITH, AND H. F. WEST Sheffield Centre for the Investigation and Treatment of Rheumatic Diseases In 1954 the first report appeared of a controlled rates and strengths of grip of the 21 patients from trial of aspirin versus cortisone in the treatment of this Centre who took part in the trial. Had a 1 to 5 early cases ofrheumatoid arthritis (Medical Research prednisone to cortisone dose been employed, the Council-Nuffield Foundation Joint Committee, therapeutic superiority of prednisone, of which 1954). The trial showed that, after treatment for we are now aware, would have been apparent. More a year, the group receiving cortisone (mean dose recently, fourteen patients from this trial who had 75 mg. daily) had fared no better than that receiving been kept on cortisone for a second year were only aspirin. Some of the patients had had radio- transferred to prednisolone. On this occasion the graphs taken of their hands and feet at the start dose ratio employed was 1 to 6 prednisolone to of the trial and at the end of the first year. Bone cortisone. By the end of 6 months their mean erosion was found to have advanced in both groups. erythrocyte sedimentation rate (Wintrobe) had The score for advance was slightly greater in the fallen from 24-6 to 15 mm./hr, and their mean aspirin group, but the difference was not statis- strength of grip had risen from 271 to 299 mm.
    [Show full text]
  • Cortisol Deficiency and Steroid Replacement Therapy
    Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Cortisol deficiency and steroid replacement therapy This leaflet explains about cortisol deficiency and how it is treated. It also contains information about how to deal with illnesses, accidents and other stressful events in children on cortisol replacement. Where are the The two most important ones are: adrenal glands and • Aldosterone – this helps regulate what do they do? the blood pressure by controlling how much salt is retained in the The adrenal glands rest on the tops body. If a person is unable to of the kidneys. They are part of the make aldosterone themselves, they endocrine system, which organises the will need to take a tablet called release of hormones within the body. ‘fludrocortisone’. Hormones are chemical messengers that switch on and off processes within the • Cortisol – this is the body’s natural body. steroid and has three main functions: The adrenal glands consist of two parts: - helping to control the blood the medulla (inner section) which sugar level makes the hormone ‘adrenaline’ which is part of the ‘fight or flight’ - helping the body deal with stress response a person has when stressed. - helping to control blood pressure the cortex (outer section) which and blood circulation. releases several hormones. If a person is unable to make cortisol themselves, they will need to take a tablet to replace it. Pituitary gland The most common form used is hydrocortisone, but other forms Parathyroid gland may be prescribed. Thyroid gland Medulla Cortex Adrenal Thymus gland Gland Kidney Adrenal gland Pancreas Sheet 1 of 7 Ref: 2014F0715 © GOSH NHS Foundation Trust March 2015 What is In these circumstances, the amount cortisol deficiency? of hydrocortisone given needs to be increased quickly.
    [Show full text]
  • Cortisone Injections
    Pain & Rehab Medicine 920‐288‐8377/888‐965‐4380 Cortisone Injections Why are these procedures done? Cortisone is a treatment for inflammation. Most literature on painful conditions of the spine and joints suggest that inflammation can be a key contributor to the pain in addition to ligament, tendon and cartilage damage. It is very important to note that these injections/procedures are almost NEVER a cure for the problem. These procedures are used as a tool to advance your therapy and exercise program. When you find your therapy or exercise program too painful – cortisone injections can be of great value in lessening the inflammation/pain to allow for more effective therapeutic intervention. Possible side effects: Cortisone or Steroid Flare Reaction ‐ Sometimes people experience a delayed (within 24‐48 hours), temporary (lasting 24‐48 hours) increase in their pain. Icing can be helpful. You should not be concerned if you experience this side effect. It will not change the effectiveness of the shot. Elevated Blood Pressure ‐ Most commonly occurs in patients who are already hypertensive. This happens because of temporary fluid retention and may be accompanied by an increased swelling of the feet. This effect is temporary. Elevated Blood Sugar ‐ Most commonly seen in diabetic patients. Patients with diabetes should carefully monitor their blood sugar as cortisone can cause a temporary rise in glucose levels. If you take insulin you should be especially careful. Check your blood sugar often and adjust the insulin doses if necessary. Facial Flushing ‐ A flushing sensation and redness of the face. This reaction is more common in women and is seen in up to 15 percent of patients.
    [Show full text]
  • Determination of Steroid Hormones and Their Metabolite in Several
    G Model CHROMA-359178; No. of Pages 10 ARTICLE IN PRESS Journal of Chromatography A, xxx (2018) xxx–xxx Contents lists available at ScienceDirect Journal of Chromatography A journal homepage: www.elsevier.com/locate/chroma Determination of steroid hormones and their metabolite in several types of meat samples by ultra high performance liquid chromatography—Orbitrap high resolution mass spectrometry ∗ Marina López-García, Roberto Romero-González, Antonia Garrido Frenich Research Group “Analytical Chemistry of Contaminants”, Department of Chemistry and Physics, Research Centre for Agricultural and Food Biotechnology (BITAL), University of Almeria, Agrifood Campus of International Excellence, ceiA3, E-04120, Almería, Spain a r t i c l e i n f o a b s t r a c t Article history: A new analytical method based on ultra-high performance liquid chromatography (UHPLC) coupled Received 8 November 2017 to Orbitrap high resolution mass spectrometry (Orbitrap-HRMS) has been developed for the deter- Received in revised form 23 January 2018 mination of steroid hormones (hydrocortisone, cortisone, progesterone, prednisone, prednisolone, Accepted 28 January 2018 testosterone, melengesterol acetate, hydrocortisone-21-acetate, cortisone-21-acetate, testosterone Available online xxx ␣ propionate, 17 -methyltestosterone, 6␣-methylprednisolone and medroxyprogesterone) and their metabolite (17␣-hydroxyprogesterone) in three meat samples (chicken, pork and beef). Two differ- Keywords: ent extraction approaches were tested (QuEChERS “quick, easy, cheap, effective, rugged and safe” and Meat Hormones “dilute and shoot”), observing that the QuEChERS method provided the best results in terms of recov- Steroids ery. A clean-up step was applied comparing several sorbents, obtaining the best results when florisil Metabolite and aluminum oxide were used.
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ...................................................
    [Show full text]
  • The Novel Progesterone Receptor
    0013-7227/99/$03.00/0 Vol. 140, No. 3 Endocrinology Printed in U.S.A. Copyright © 1999 by The Endocrine Society The Novel Progesterone Receptor Antagonists RTI 3021– 012 and RTI 3021–022 Exhibit Complex Glucocorticoid Receptor Antagonist Activities: Implications for the Development of Dissociated Antiprogestins* B. L. WAGNER†, G. POLLIO, P. GIANGRANDE‡, J. C. WEBSTER, M. BRESLIN, D. E. MAIS, C. E. COOK, W. V. VEDECKIS, J. A. CIDLOWSKI, AND D. P. MCDONNELL Department of Pharmacology and Cancer Biology (B.L.W., G.P., P.G., D.P.M.), Duke University Medical Center, Durham, North Carolina 27710; Molecular Endocrinology Group (J.C.W., J.A.C.), NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709; Department of Biochemistry and Molecular Biology (M.B., W.V.V.), Louisiana State University Medical School, New Orleans, Louisiana 70112; Ligand Pharmaceuticals, Inc. (D.E.M.), San Diego, California 92121; Research Triangle Institute (C.E.C.), Chemistry and Life Sciences, Research Triangle Park, North Carolina 27709 ABSTRACT by agonists for DNA response elements within target gene promoters. We have identified two novel compounds (RTI 3021–012 and RTI Accordingly, we observed that RU486, RTI 3021–012, and RTI 3021– 3021–022) that demonstrate similar affinities for human progeste- 022, when assayed for PR antagonist activity, accomplished both of rone receptor (PR) and display equivalent antiprogestenic activity. As these steps. Thus, all three compounds are “active antagonists” of PR with most antiprogestins, such as RU486, RTI 3021–012, and RTI function. When assayed on GR, however, RU486 alone functioned as 3021–022 also bind to the glucocorticoid receptor (GR) with high an active antagonist.
    [Show full text]
  • Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice
    diagnostics Review Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice Katarzyna Pelewicz and Piotr Mi´skiewicz* Department of Internal Medicine and Endocrinology, Medical University of Warsaw, 02-091 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-225-992-877 Abstract: Glucocorticoids (GCs) are widely used due to their anti-inflammatory and immunosup- pressive effects. As many as 1–3% of the population are currently on GC treatment. Prolonged therapy with GCs is associated with an increased risk of GC-induced adrenal insufficiency (AI). AI is a rare and often underdiagnosed clinical condition characterized by deficient GC production by the adrenal cortex. AI can be life-threatening; therefore, it is essential to know how to diagnose and treat this disorder. Not only oral but also inhalation, topical, nasal, intra-articular and intravenous administration of GCs may lead to adrenal suppression. Moreover, recent studies have proven that short-term (<4 weeks), as well as low-dose (<5 mg prednisone equivalent per day) GC treatment can also suppress the hypothalamic–pituitary–adrenal axis. Chronic therapy with GCs is the most com- mon cause of AI. GC-induced AI remains challenging for clinicians in everyday patient care. Properly conducted GC withdrawal is crucial in preventing GC-induced AI; however, adrenal suppression may occur despite following recommended GC tapering regimens. A suspicion of GC-induced AI requires careful diagnostic workup and prompt introduction of a GC replacement treatment. The Citation: Pelewicz, K.; Mi´skiewicz,P. present review provides a summary of current knowledge on the management of GC-induced AI, Glucocorticoid Withdrawal—An including diagnostic methods, treatment schedules, and GC withdrawal regimens in adults.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator
    Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism: Results From an Open-Label Phase 2 Study Rosario Pivonello, MD, PhD1; Atil Y. Kargi, MD2; Noel Ellison, MS3; Andreas Moraitis, MD4; Massimo Terzolo, MD5 1Università Federico II di Napoli, Naples, Italy; 2University of Miami Miller School of Medicine, Miami, FL, USA; 3Trialwise, Inc, Houston, TX, USA; 4Corcept Therapeutics, Menlo Park, CA, USA; 5Internal Medicine 1 - San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy INTRODUCTION EFFICACY ANALYSES Table 5. Summary of Responder Analysis in Patients at Last SAFETY Relacorilant is a highly selective glucocorticoid receptor modulator under Key efficacy assessments were the evaluation of blood pressure in the Observation Table 7 shows frequency of TEAEs; all were categorized as ≤Grade 3 in hypertensive subgroup and glucose tolerance in the impaired glucose severity investigation for the treatment of all etiologies of endogenous Cushing Low-Dose Group High-Dose Group tolerance (IGT)/type 2 diabetes mellitus (T2DM) subgroup Five serious TEAEs were reported in 4 patients in the high-dose group syndrome (CS) Responder, n/N (%) Responder, n/N (%) o Relacorilant reduces the effects of cortisol, but unlike mifepristone, does o Response in hypertension defined as a decrease of ≥5 mmHg in either (pilonidal cyst, myopathy, polyneuropathy, myocardial infarction, and not bind to progesterone receptors (Table 1)1 mean systolic blood pressure (SBP) or diastolic blood pressure (DBP) from HTN 5/12 (41.67) 7/11 (63.64) hypertension) baseline No drug-induced cases of hypokalemia or abnormal vaginal bleeding were IGT/T2DM 2/13 (15.38) 6/12 (50.00) o Response in IGT/T2DM defined by one of the following: noted Table 1.
    [Show full text]
  • CORTISOL IMBALANCE Patient Handout
    COMMON PATTERNS OF CORTISOL IMBALANCE Patient HandOut Cortisol that does not follow the normal pattern can trigger blood sugar imbalances, food cravings and fat storage, especially around the middle. Related imbalances of low DHEA commonly result in loss of lean muscle, lack of strength, decreased stamina and low exercise tolerance. Chronically Elevated Cortisol Overall higher than normal cortisol Lifestyle suggestions: production throughout the day from • Reduce stress and improve coping skills prolonged stress demands. High • Protein at each meal, no skipping lunch cortisol also depletes its precursor hormone progesterone. • Hydrate throughout the day, herbal teas and water, avoid soft drinks General symptoms: • Reduce consumption of refined carbohydrates and caffeine • Food/sugar cravings • Get adequate sleep (at least 7 hours); catnaps • Feeling “tired but wired” • Aerobic exercise: <40 min low – moderate intensity • Insomnia during time when cortisol level within optimal range • Anxiety • Strength training: with guidance 2-3 times per week • Enjoy exercise that decreases excessive stress symptoms Steep Drop in Cortisol • Exercise in the morning Stress/fatigued pattern – morning Lifestyle suggestions: cortisol in the high normal range or • Reduce stress and improve coping skills elevated, but levels drop off rapidly, • Protein at each meal, no skipping lunch indicating adrenal dysfunction. • Hydrate throughout the day, herbal teas General symptoms: and water, avoid soft drinks • Mid-day energy drop • Reduce consumption of refined carbohydrates and caffeine • Drowsiness • Get adequate sleep (at least 7 hours); catnaps • Caffeine/sugar cravings • Exercise mid morning to boost energy with a combination • Low exercise tolerance/ of muscle building and cardiovascular activities poor recovery • Schedule more time for fun activities Rebound Cortisol Up and down/ irregular cortisol, Lifestyle suggestions: not following the normal pattern.
    [Show full text]
  • Sleep Deprivation on the Nighttime and Daytime Profile of Cortisol Levels
    Sleep. 20(10):865-870 © 1997 American Sleep Disorders Association and Sleep Research Society Sleep Loss Sleep Loss Results in an Elevation of Cortisol Levels the Next Evening Downloaded from https://academic.oup.com/sleep/article/20/10/865/2725962 by guest on 30 September 2021 *Rachel Leproult, tGeorges Copinschi, *Orfeu Buxton and *Eve Van Cauter *Department of Medicine, University of Chicago, Chicago, Illinois, U.S.A.; and tCenter for the Study of Biological Rhythms and Laboratory of Experimental Medicine, Erasme Hospital, Universite Libre de Bruxelles, Brussels, Belgium Summary: Sleep curtailment constitutes an increasingly common condition in industrialized societies and is thought to affect mood and performance rather than physiological functions. There is no evidence for prolonged or delayed effects of sleep loss on the hypothalamo-pituitary-adrenal (HPA) axis. We evaluated the effects of acute partial or total sleep deprivation on the nighttime and daytime profile of cortisol levels. Plasma cortisol profiles were determined during a 32-hour period (from 1800 hours on day I until 0200 hours on day 3) in normal young men submitted to three different protocols: normal sleep schedule (2300-0700 hours), partial sleep deprivation (0400-0800 hours), and total sleep deprivation. Alterations in cortisol levels could only be demonstrated in the evening following the night of sleep deprivation. After normal sleep, plasma cortisol levels over the 1800-2300- hour period were similar on days I and 2. After partial and total sleep deprivation. plasma cortisol levels over the 1800-2300-hour period were higher on day 2 than on day I (37 and 45% increases, p = 0.03 and 0.003, respec­ tively), and the onset of the quiescent period of cortisol secretion was delayed by at least I hour.
    [Show full text]